New York State health regulators have accused an aesthetics company of running a clandestine operation to bring an injectable cosmetic filler derived from human cadaver tissue into the state without the required license. The allegations, detailed in a court filing last month, center on alloClae, a product sold by Tiger Aesthetics that uses sterilized fat tissue from deceased donors.
According to Business Insider, a state attorney claimed that Tiger and its affiliates engaged in a “year-long scheme to smuggle alloClae” into New York. The product, which can be injected without anesthetic, has gained popularity in cosmetic procedures despite its unusual origin. The state's health department argues that Tiger operated without the necessary distribution license, a charge the company denies.
Tiger Aesthetics has pushed back, filing a lawsuit against the health department. The company contends that the state lacks the authority to regulate alloClae because New York law does not require licenses for sterilized products of this kind. Instead, Tiger argues, the product falls under the jurisdiction of the U.S. Food and Drug Administration (FDA), where premarket approval is not mandated for such items.
The legal battle has yet to produce a decisive ruling. In late May, a judge declined to block the state's crackdown on alloClae but also refused to halt distribution of a separate Tiger product that was the subject of another lawsuit. This mixed outcome leaves both sides claiming partial victories.
Legal experts following the case note that the outcome could hinge on several factors. Hermes Fernandez, a lawyer representing healthcare industry clients, told Business Insider that the case could go either way. He pointed out that other states have not challenged alloClae, which might work in Tiger's favor. However, if Tiger voluntarily submitted to a permitting process and then bypassed it, that could undermine its position. “Regulators tend not to like that,” Fernandez said.
Product Availability Hangs in the Balance
In response to the ongoing litigation, Tiger has told customers in a letter that it has “decided temporarily to pause” distribution in New York. Despite this, Business Insider reports that many plastic surgery clinics in the state still advertise alloClae. Some are taking a cautious approach, with one major clinic describing the product as “revolutionary” on its website while also posting a notice that alloClae is not currently approved by the New York State Department of Health.
The case raises broader questions about the regulation of cosmetic injectables derived from human tissue. While the FDA oversees many such products, state-level licensing requirements can create a patchwork of rules. The dispute between Tiger and New York regulators could set a precedent for how other states handle similar products.
For now, the legal status of alloClae in New York remains unresolved. The judge's recent rulings suggest a cautious approach, and the final decision could have implications for the broader aesthetics industry. As the lawsuit proceeds, both regulators and the company are likely to continue their arguments over jurisdiction and licensing.





